References
- LanzaGAFoxKCreaFHeart rate: A risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowingAdv Cardiol200643116
- LurjeLWennerblomBTygesenHKarlssonTHjalmarsonAHeart rate variability after acute myocardial infarction in patients treated with atenolol and metoprololInt J Cardiol19976021571649226286
- LonnEGrewalJDrug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directionsCurr Vasc Pharmacol200643253268
- PoulterNRDobsonJESeverPSDahlofBWedelHCampbellNRBaseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo – Scandinavian Cardiac Outcomes Trial)J Am Coll Cardiol2009541311541161
- FrishmanWHA historical perspective on the development of β-adrenergic blockersJ Clin Hypertens200794 Suppl 31927
- EganBMBasileJChiltonRJCohenJDCardioprotection: The role of beta-blocker therapyJ Clin Hypertens (Greenwich)200577409416
- Lopez-SendonJSwedbergKMcMurrayJExpert consensus document on beta-adrenergic receptor blockersEur Heart J2004251513411362
- BakrisGLHartPRitzEBeta blockers in the management of chronic kidney diseaseKidney Int200670111905191317021610
- MesserliFHGrossmanEBeta-blockers in hypertension: Is carvedilol different?Am J Cardiol2004939A7B12B
- BrocqMLLeslieSJMillikenPMegsonILEndothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunitiesAntioxid Redox Signal200810916311674
- KrumHSympathetic activation and the role of beta-blockers in chronic heart failureAust N Z J Med1999293418427
- ManciaGGrassiGGiannattasioCSeravalleGSympathetic activation in the pathogenesis of hypertension and progression of organ damageHypertension1999344 Pt 272472810523349
- De JongMJRandallDCHeart rate variability analysis in the assessment of autonomic function in heart failureJ Cardiovasc Nurs2005203186195quiz 196–19715870589
- FeldmanDSEltonTSSunBMartinMMZioloMTMechanisms of disease: Detrimental adrenergic signaling in acute decompensated heart failureNat Clin Pract Cardiovasc Med200854208218
- FoxKBorerJSCammAJResting heart rate in cardiovascular diseaseJ Am Coll Cardiol2007509823830
- DiazABourassaMGGuertinMCTardifJCLong-term prognostic value of resting heart rate in patients with suspected or proven coronary artery diseaseEur Heart J2005261096797415774493
- JouvenXEmpanaJPSchwartzPJDesnosMCourbonDDucimetierePHeart-rate profile during exercise as a predictor of sudden deathN Engl J Med2005352191951195815888695
- LeeKLWoodliefLHTopolEJPredictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I InvestigatorsCirculation199591616591668
- KannelWBRisk stratification in hypertension: New insights from the Framingham StudyAm J Hypertens2000131 Pt 23S10S
- WilhelmsenLBerglundGElmfeldtDThe multifactor primary prevention trial in Goteborg, SwedenEur Heart J198674279288
- DyerARPerskyVStamlerJHeart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studiesAm J Epidemiol19801126736749
- GillumRFMakucDMFeldmanJJPulse rate, coronary heart disease, and death: The NHANES I Epidemiologic Follow-up StudyAm Heart J19911211 Pt 1172177
- GoldbergRJLarsonMLevyDFactors associated with survival to 75 years of age in middle-aged men and women. The Framingham StudyArch Intern Med19961565505509
- KannelWBWilsonPBlairSNEpidemiological assessment of the role of physical activity and fitness in development of cardiovascular diseaseAm Heart J19851094876885
- SinghBNMorbidity and mortality in cardiovascular disorders: Impact of reduced heart rateJ Cardiovasc Pharmacol Ther20016431333111907634
- KovarDCannonCPBentleyJHCharlesworthARogersWJDoes initial and delayed heart rate predict mortality in patients with acute coronary syndromes?Clin Cardiol20042728086
- EagleKALimMJDabbousOHA validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registryJAMA20042912227272733
- MarchioliRAvanziniFBarziFAssessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chartEur Heart J200122222085210311686666
- MorrowDAAntmanEMCharlesworthATIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudyCirculation20001021720312037
- ThomsenTFDavidsenMIbsenHJorgensenTJensenGBorch-JohnsenKA new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials: PRE-CARD and the Copenhagen Risk ScoreJ Cardiovasc Risk200185291297
- ConroyRMPyoralaKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE projectEur Heart J20032411987100312788299
- ChattipakornNIncharoenTKanlopNChattipakornSHeart rate variability in myocardial infarction and heart failureInt J Cardiol2007120328929617349699
- Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and ElectrophysiologyCirculation1996935104310658598068
- ReilJCBohmMThe role of heart rate in the development of cardiovascular diseaseClin Res Cardiol2007969585592
- YoungJBSudden cardiac death syndrome and pump dysfunction: The linkJ Heart Lung Transplant200019Suppl 8S27S31
- NesslerJNesslerBKitlinskiMSudden cardiac death risk factors in patients with heart failure treated with carvedilolKardiol Pol2007651214171422discussion 1423–142418181053
- KjekshusJGullestadLHeart rate as a therapeutic target in heart failureEur Heart J Suppl19991Suppl HH64H69
- FlanneryGGehrig-MillsRBillahBKrumHAnalysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockersAm J Cardiol2008101686586918328855
- HuangRLListermanJGoringJGiesbergCNadingMAButlerJBeta-blocker therapy for heart failure: Should the therapeutic target be dose or heart rate reduction?Congest Heart Fail200612420610quiz 211–212
- LechatPEscolanoSGolmardJLPrognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS)Circulation1997967219722059337190
- LechatPHulotJSEscolanoSHeart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II TrialCirculation2001103101428143311245648
- DargieHJEffect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trialLancet2001357926613851390
- PackerMCoatsAJFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med2001344221651165811386263
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet1999353916920012007
- Poole-WilsonPASwedbergKClelandJGComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trialLancet2003362937771312853193
- FeldmanDSCarnesCAAbrahamWTBristowMRMechanisms of disease: Beta-adrenergic receptors – alterations in signal transduction and pharmacogenomics in heart failureNat Clin Pract Cardiovasc Med200529475483
- Veteran’s Health Administration Pharmacy Benefits Management Services and the Medical Advisory PanelNational PBM drug monograph: Nebivolol (Bystolic)20086 www.pbm.va.gov/monograph/Nebivolol.doc. Accessed Feb 18, 2009
- Agabiti RoseiERizzoniDMetabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristicsDrugs200767810971107
- SimonGJohnsonMLComparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertensionClin Exp Hypertens19931535015098098243
- KampOSieswerdaGTVisserCAComparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertensionAm J Cardiol2003923344348
- StoschitzkyKStoschitzkyGBrusseeHBonelliCDobnigHComparing beta-blocking effects of bisoprolol, carvedilol and nebivololCardiology20061064199206
- PatrianakosAPParthenakisFIMavrakisHEDiakakisGFChlouverakisGIVardasPEComparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month studyAm Heart J20051505985
- NesslerJNesslerBKitlinskiMGackowskiAPiwowarskaWStepniewskiMConcentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilolKardiol Pol2008662144151discussion 152–15318344152
- OlssonLGSwedbergKClarkALWitteKKClelandJGSix minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic reviewEur Heart J2005268778793
- JafriSMThe effects of beta blockers on morbidity and mortality in heart failureHeart Fail Rev200492115121
- ShibataMCFlatherMDWangDSystematic review of the impact of beta blockers on mortality and hospital admissions in heart failureEur J Heart Fail20013335135711378007
- KitzmanDWExercise intoleranceProg Cardiovasc Dis2005476367379
- JordeUPVittorioTJKasperMEChronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: Time to pace?Eur J Heart Fail200810196101
- LauerMSLarsonMGEvansJCLevyDAssociation of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart StudyAm Heart J1999137590390910220640
- LauerMSOkinPMLarsonMGEvansJCLevyDImpaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart StudyCirculation1996938152015268608620
- WitteKKClarkALChronotropic incompetence in heart failureJ Am Coll Cardiol2006483595author reply 595–596
- KhanMNPothierCELauerMSChronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol)Am J Cardiol20059691328133316253608
- MyersJTanSYAbellaJAletiVFroelicherVFComparison of the chronotropic response to exercise and heart rate recovery in predicting cardiovascular mortalityEur J Cardiovasc Prev Rehabil2007142215221
- WeissRNebivolol: A novel beta-blocker with nitric oxide-induced vasodilatationVasc Health Risk Manag200623303308
- CarvalhoVORodrigues AlvesRXBocchiEAGuimaraesGVHeart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy Heart rate dynamic during exercise testInt J Cardiol2009118[Epub ahead of print]
- VittorioTJZoltyRKasperMEDifferential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failureJ Cardiovasc Pharmacol Ther20081315157
- SteckerECFendrickAMKnightBPAaronsonKDProphylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardiaAm Heart J20061514820828
- HeidlandUEStrauerBELeft ventricular muscle mass and elevated heart rate are associated with coronary plaque disruptionCirculation20011041314771482
- HjalmarsonAGilpinEAKjekshusJInfluence of heart rate on mortality after acute myocardial infarctionAm J Cardiol19906595475531968702
- AbildstromSZJensenBTAgnerEHeart rate versus heart rate variability in risk prediction after myocardial infarctionJ Cardiovasc Electrophysiol2003142168173
- SteinPKDomitrovichPPHuikuriHVKleigerRETraditional and nonlinear heart rate variability are each independently associated with mortality after myocardial infarctionJ Cardiovasc Electrophysiol20051611320
- ZuanettiGHernndes-BernalFRossiAComerioGPaolucciGMaggioniAPRelevance of heart rate as a prognostic factor in myocardial infarction: The GISSI experienceEur Heart J Suppl19991Suppl HH52H57
- KjekshusJKImportance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trialsAm J Cardiol1986571243F49F
- GundersenTGrottumPPedersenTKjekshusJKEffect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at restAm J Cardiol19865812024
- TuiningaYSCrijnsHJBrouwerJEvaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patientsCirculation19959212341534238521562
- LampertRIckovicsJRViscoliCJHorwitzRILeeFAEffects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack TrialAm J Cardiol2003912137142
- BasuSSeniorRRavalUvan der DoesRBrucknerTLahiriABeneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trialCirculation1997961183191
- LouisWJMcNeilJJDrummerOHPharmacology of combined alpha-beta-blockade. IDrugs198428Suppl 21634
- PedersenMECockcroftJRThe vasodilatory beta-blockersCurr Hypertens Rep200794269277
- MacCarthyEPBloomfieldSSLabetalol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effectsPharmacotherapy1983341932196310529
- VermaSPSilkeBHussainMSympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipineJ Hypertens1988611897904
- StoleruLWijnsWvan EyllCBouvyTVan NuetenLPouleurHEffects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: Comparison with D-L-nebivolol and atenololJ Cardiovasc Pharmacol1993222183190
- PalatiniPGranieroGRMorminoPRelation between physical training and ambulatory blood pressure in stage I hypertensive subjects. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia StudyCirculation199490628702876
- BohmMReilJCDanchinNThoenesMBramlagePVolpeMAssociation of heart rate with microalbuminuria in cardiovascular risk patients: Data from I-SEARCHJ Hypertens2008261182518090536
- MadsenLBRasmussenJKMollerDSNyvadOPedersenEBHeart rate variability in white-coat hypertensionBlood Press Monit20081326571
- GillmanMWKannelWBBelangerAD’AgostinoRBInfluence of heart rate on mortality among persons with hypertension: The Framingham StudyAm Heart J1993125411481154
- LevyBImportance of improving tissue perfusion during treatment of hypertensionJ Hypertens Suppl2006245S6S9
- LevyBI[The importance of microcirculation and tissue perfusion in hypertension]Curr Med Res Opin200521Suppl 5S1S6
- CampeloMPoloniaJSerraoPCerqueira-GomesMEvaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenololCardiology1996875402408
- ChernCMHsuHYHuHHChenYYHsuLCChaoACEffects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertensionJ Cardiovasc Pharmacol2006472169174
- Lund-JohansenPHemodynamic consequences of long-term beta-blocker therapy: A 5-year follow-up study of atenololJ Cardiovasc Pharmacol197915487495
- BangaloreSParkarSGrossmanEMesserliFHA meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitusAm J Cardiol200710081254126217920367
- BradleyHAWiysongeCSVolminkJAMayosiBMOpieLHHow strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysisJ Hypertens200624112131214117053529
- CruickshankJMAre we misunderstanding beta-blockersInt J Cardiol200712011027
- SarafidisPABakrisGLDo the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?J Clin Hypertens (Greenwich)200685351356quiz 357–35816687944
- StafylasPCSarafidisPACarvedilol in hypertension treatmentVasc Health Risk Manag200841233018629377
- WeberMABakrisGLTarkaEAIyengarMFleckRSicaDAEfficacy of a once-daily formulation of carvedilol for the treatment of hypertensionJ Clin Hypertens (Greenwich)2006812840849
- BakrisGLFonsecaVKatholiREMetabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trialJAMA2004292182227223615536109
- von FalloisJFaulhaberHD[Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study]Fortschr Med Orig2000118Suppl 2778215700490
- MunzelTGoriTNebivolol: The somewhat-different beta-adrenergic receptor blockerJ Am Coll Cardiol2009541614911499
- SchmidtACFlickBJahnEBramlagePEffects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteersVasc Health Risk Manag20084490991519066009
- BangaloreSSawhneySMesserliFHRelation of beta-blocker-induced heart rate lowering and cardioprotection in hypertensionJ Am Coll Cardiol2008521814821489